Advancing HFpEF Treatment with Novel MRAs - Episode 6
Nonsteroidal vs Steroidal MRAs in HFpEF
The conversation compares the efficacy and safety of nonsteroidal and steroidal MRAs, focusing on clinical decision-making and patient selection.
Panelists compared the profiles of steroidal and nonsteroidal mineralocorticoid receptor antagonists (MRAs), noting key differences in safety and tolerability. Traditional agents such as spironolactone can improve outcomes but often raise concerns about hyperkalemia and hormonal adverse effects.
Finerenone, a nonsteroidal MRA, was highlighted for its targeted receptor activity and reduced risk of electrolyte imbalance. The discussion emphasized its value for patients with comorbid diabetes and chronic kidney disease, where treatment balance is delicate.
Experts agreed that MRA choice should depend on renal function, metabolic profile, and individual risk. Nonsteroidal options may offer greater flexibility and adherence in complex care of heart failure with preserved ejection fraction. outcome disparities across the HFpEF population.
